LineaBio
Berkeley, United States· Est.
A platform delivering GMP‑grade iPSC lines to speed cell‑therapy development.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A platform delivering GMP‑grade iPSC lines to speed cell‑therapy development.
Cell therapyGene therapy
Technology Platform
GMP‑compliant iPSC manufacturing platform using Sendai‑virus reprogramming, clonal selection, extensive QC, and optional gene editing, all supported by drug master files for regulatory submissions.
Opportunities
Growing demand for GMP‑grade iPSC lines to accelerate cell‑therapy development and reduce CMC costs across multiple therapeutic areas.
Risk Factors
Regulatory uncertainties for iPSC‑derived products and competition from established GMP iPSC providers could limit market adoption.
Competitive Landscape
Key competitors include Fujifilm Cellular Dynamics, Thermo Fisher Scientific, and Stemcell Technologies; LineaBio differentiates through its integrated DMF support and flexible licensing model.